HALOGENATED ANALOGS OF TAMOXIFEN - SYNTHESIS, RECEPTOR ASSAY, AND INHIBITION OF MCF7-CELLS

被引:16
作者
YANG, DJ
TEWSON, T
TANSEY, W
KUANG, LR
REGER, G
CHERIF, A
WRIGHT, KC
MOULT, RG
TILBURY, RS
CHU, K
KIM, EE
WALLACE, S
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DIV MED ONCOL,HOUSTON,TX 77030
[2] UNIV TEXAS,HLTH SCI CTR,POSITRON DIAGNOST RES CTR,HOUSTON,TX 77030
关键词
D O I
10.1002/jps.2600810706
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study was conducted to develop a ligand for imaging estrogen-receptor-positive breast tumors by positron emission tomography or single photon emission computed tomography. We synthesized fluoro and iodo analogues of tamoxifen, and these halogenated analogues produced greater affinity for binding to the receptor than tamoxifen. Values of the inhibition affinity constants were as follows: tamoxifen, 15 000 nM; fluoromethyl-N,N-diethyltamoxifen, 2500 nM for the cis isomer and 500 nM for the trans isomer; and iodomethyl-N,N-diethyltamoxifen, 1500 nM for the cis isomer and 1000 nM for the trans isomer. In studies of human MCF7 breast tumor cell growth, concentrations that inhibited tumor growth in 50% of the cases were as follows: tamoxifen, 11-mu-M; fluoromethyl-N,N-diethyltamoxifen, 4.5 and 11.8-mu-M for the cis and trans isomers, respectively; and iodomethyl-N,N-diethyltamoxifen, 2.4 and 6.3-mu-M for the cis and trans isomers, respectively. These studies suggest that both fluoro and iodo analogues of tamoxifen may be useful diagnostic compounds for predicting the response of estrogen-receptor-positive breast tumors to tamoxifen analogues used in chemotherapy.
引用
收藏
页码:622 / 625
页数:4
相关论文
共 18 条
[1]  
FERNANDEZ MD, 1984, EUR J CANCER CLIN ON, V20, P41
[2]  
FISHMAN JH, 1983, BIOCHEM BIOPH RES CO, V110, P73
[3]   HYDROXY DERIVATIVES OF TAMOXIFEN [J].
FOSTER, AB ;
JARMAN, M ;
LEUNG, OT ;
MCCAGUE, R ;
LECLERCQ, G ;
DEVLEESCHOUWER, N .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (10) :1491-1497
[4]  
FOSTER AB, 1986, ANTI-CANCER DRUG DES, V1, P245
[5]  
HAMACHER K, 1986, J NUCL MED, V27, P235
[6]   A NEW TRIPHENYLETHYLENE COMPOUND, FC-1157A .1. HORMONAL EFFECTS [J].
KALLIO, S ;
KANGAS, L ;
BLANCO, G ;
JOHANSSON, R ;
KARJALAINEN, A ;
PERILA, M ;
PIPPO, I ;
SUNDQUIST, H ;
SODERVALL, M ;
TOIVOLA, R .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (02) :103-108
[7]   A NEW TRIPHENYLETHYLENE COMPOUND, FC-1157A .2. ANTITUMOR EFFECTS [J].
KANGAS, L ;
NIEMINEN, AL ;
BLANCO, G ;
GRONROOS, M ;
KALLIO, S ;
KARJALAINEN, A ;
PERILA, M ;
SODERVALL, M ;
TOIVOLA, R .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (02) :109-113
[8]  
KATZENELLENBOGEN BS, 1984, CANCER RES, V44, P112
[9]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[10]   SYNTHESIS, CONFORMATIONAL CONSIDERATIONS, AND ESTROGEN-RECEPTOR BINDING OF DIASTEREOISOMERS AND ENANTIOMERS OF 1-[4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL]-1,2-DIPHENYLBUTANE (DIHYDROTAMOXIFEN) [J].
MCCAGUE, R ;
LECLERCQ, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (10) :1761-1767